The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boriskina L.N.

Volgograd brunch of S.N. Fedorov National Medical Research Center «MNTK «Eye Microsurgery»

The significance of choroidal neovascularization type in predicting the effectiveness of antiangiogenic therapy

Authors:

Boriskina L.N.

More about the authors

Journal: Russian Annals of Ophthalmology. 2021;137(5): 146‑151

DOI: 10.17116/oftalma2021137051146

Read: 2326 times

Download PDF (RU)
Contact the author
Table of contents

THE SIGNIFICANCE OF CHOROIDAL NEOVASCULARIZATION TYPE IN PREDICTING THE EFFECTIVENESS OF ANTIANGIOGENIC THERAPY
THE SIGNIFICANCE OF CHOROIDAL NEOVASCULARIZATION TYPE IN PREDICTING THE EFFECTIVENESS OF ANTIANGIOGENIC THERAPY

To cite this article:

Boriskina LN. The significance of choroidal neovascularization type in predicting the effectiveness of antiangiogenic therapy. Russian Annals of Ophthalmology. 2021;137(5):146‑151. (In Russ.)
https://doi.org/10.17116/oftalma2021137051146

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Asso­ciation between inte­grity of foveal photoreceptors and ulti­mate visual outcome in neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2025;(1):32-36
Choroidal neovascularization asso­ciated with choroidal nevi. Russian Annals of Ophthalmology. 2025;(1):104-112
New options dete­rmining the success of treatment for neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2025;(3):71-78
Algo­rithm for predicting treatment outcomes in vascular pigment epithelial deta­chment in neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2025;(4):12-18
Use of fari­cimab in neovascular age-related macu­lar dege­neration and diabetic macu­lar edema in Russia. Resu­lts of the FARWATER retrospective study. Russian Annals of Ophthalmology. 2025;(6):82-91
Abstract:

Neovascular age-related macular degeneration (nAMD) is one of the causes of irreversible visual acuity loss. Intravitreal injections of anti-vascular endothelium growth factor (anti-VEGF agents) have been proved to be an effective treatment of nAMD. Among the topical problems of this type of treatment is the possibility for predicting the response of different types of choroidal neovascularization (CNV) to the anti-VEGF therapy. This article discusses the differences in the dynamics of morphological and functional parameters of various types of neovascular membranes in the process of anti-VEGF therapy.

Keywords:

neovascular age-related macular degeneration
types of macular neovascularization
antiangiogenic therapy

Authors:

Boriskina L.N.

Volgograd brunch of S.N. Fedorov National Medical Research Center «MNTK «Eye Microsurgery»

Received:

22.07.2021

Accepted:

24.08.2021

Close metadata

References:

  1. Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analisys. Ophthalmology. 2008;115:116-126.  https://doi.org/10.1016/j.ophtha.2007.03.008
  2. Ferrara N, Chen H, Schroall RH. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med. 1998;4:336-340.  https://doi.org/10.1038/nm0398-336
  3. Rosenfeld PJ, Brown DM, Haier JS, et al. MARINE Study Group. Ranibizumb for neovascular age-related macular degeneration. N Eng J Med. 2006;355(14):1419-1431. https://doi.org/10.1056/NEJMoa054481
  4. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Eng J Med. 2006;355(14):1432-1444. https://doi.org/10.1056/NEJMoa062655
  5. Singer MA, Awh CC, Sadda S, et al. HORIZON-an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175-1183. https://doi.org/10.1016/j.ophtha.2011.12.016
  6. CATT Research Group; Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398. https://doi.org/10.1016/j.ophtha.2012.03.053
  7. IVAN Study Investigators; Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year finding from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399-1411. https://doi.org/10.1016/j.ophtha.2012.04.015
  8. Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201.  https://doi.org/10.1016/j.ophtha.2013.08.011
  9. Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146-152.  https://doi.org/10.1016/j.ophtha.2014.07.041
  10. Richard G, Mones J, Wolf S, et al. Scheduled versus pro re nata dosing in VIEW trials. Ophthalmology. 2015;122(12):2497-2503. https://doi.org/10.1016/j.ophtha.2015.08.014
  11. Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122(12):2514-2522. https://doi.org/10.1016/j.ophtha.2015.08.009
  12. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Brit J Ophthalmol. 2014;98(9): 1144-1167. https://doi.org/10.1136/bjophthalmol-2014-305702
  13. Klinicheskiye rekomendatsii: Vozrastnaya makulyarnaya degeneratsiya. Obshcherossiyskaya obshchestvennaya organizatsiya «Assotsiatsiya vrachey-oftal’mologov» [Clinical guidelines: Age-related macular degeneration. All-Russian public organization «Association of ophthalmologists»]. 2017 (In Russ.). https://avo-portal.ru/doc/fkr/item/261-vozrastnaya-makulyarnayadegeneratsiya
  14. Eleftheriadou M, Jemenetzi M, Lukic M, et al. Three-year outcomes of aflibercept treatment for neovascular degeneration: evidence from a clinical setting. Ophthalmol Ther. 2018;7:361-368.  https://doi.org/10.1007/s40123-018-0139-5
  15. Mantel J, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251: 697-704.  https://doi.org/10.1007/s00417-012-2090-9
  16. Holz FY, Tadayoni R, Beatty S, et al. Key drives of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA Study. Br J Ophthalmol. 2016;100:1623-1628. https://doi.org/10.1136/bjophthalmol-2015-308166
  17. Traine PY, Pfister JB, Kandi S, et al. Long-term outcome of intraviteral aflibercept treatment for neovascular age-related macular degeneration using a «treat-and-extend» regimen. Ophthalmol Retina. 2019;3(5):393-399. 
  18. Ciaulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients. Ophthalmol Retina. 2020;4(1):19-30.  https://doi.org/10.1016/j.oret.2019.05.017
  19. Neroev VV. Russia’s nationwide epidemiological noninvasive study of patients with wet age-related macular degeneration. Rossiyskiy oftal’mologicheskiy zhurnal = Russian Ophthalmological Journal. 2011;(2):4-9. (In Russ.).
  20. Fursova A, Chubar N, Tarasov M, Vasilyeva V, Gusarevich O. Anti-VEGF therapy for age-related macular degeneration. Vestnik oftal′mologii. 2018; 134(6):59-67. (In Russ.). https://doi.org/10.17116/oftalma201813406159
  21. Shelankova A, Budzinskaya M, Andreeva I, Afanasyeva M. Real clinical practice of antiangiogenic therapy in patients with age-related macular degeneration. Retrospective analysis of functional results. Vestnik oftal′mologii. 2020;136(4):207-213. (In Russ.). https://doi.org/10.17116/oftalma2020136042207
  22. Fursova A, Chubar N, Tarasov M, et al. Prognostic factors of the effectiveness of anti-angiogenic therapy in neovascular age-related macular degeneration. Vestnik oftal′mologii. 2018;134(1):48-55. (In Russ.). https://doi.org/10.17116/oftalma2018134148-55
  23. Kamenskikh T. A differentiated approach to the analysis of retinal fluid and assessment of its effect on anti-VEGF therapy of neovascular age-related degeneration. Vestnik oftal′mologii. 2019;135(6):134-140. (In Russ.). https://doi.org/10.17116/oftalma2019135061134
  24. Macular Photocoagulation Study Research Group. Subfoveal neovascular lesions in age-related macular degeneration. Arch Ophthalmol. 1991;109(9): 1242-1257.
  25. Spaide RF, Jaffe TJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data. Ophthalmology. 2020; 127(5):616-636.  https://doi.org/10.1016/j.ophtha.2019.11.004
  26. Steinle NC, Du W, Gibson A, Saroj N. Outcomes by baseline choroidal neovascularization features in age-related macular degeneration. A post-hoc analysis of the VIEW studies. Ophthalmol Retina. 2021;5(2):141-150.  https://doi.org/10.1016/j.oret.2020.07.003
  27. Li J, Xu J, Chen Y, et al. Efficacy comparison of intravitreal anti-VEGF therapy for three subtypes of neovascular age-related macular degeneration: a systematic review and meta-analysis. Hindawi J Ophthalmol. 2018;2018: 1425707. https://doi.org/10.1155/2018/1425707
  28. Chen X, Al-Sheikh M, Chan CK, et al. Type 1 versus type 3 neovascularization in pigment epithelium detachments associated with age-related macular degeneration after antivascular endothelial growth factor therapy. A prospective study. Retina. 2016;36(1):50-64.  https://doi.org/10.1097/IAE.0000000000001271
  29. Ebneter A, Michels S, Pruente C, et al. Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration. Sci Rep. 2020;10(1):20256. https://doi.org/10.1038/s41598-020-76354-1
  30. Invernizzi A, Nguyen V, Teo K, et al. Five-year real-world outcomes of occult and classic choroidal neovascularization: data from the Fight Retinal Blindness! Project. Am J Ophthalmol. 2019;204:105-112.  https://doi.org/10.1016/j.ajo.2019.03.001
  31. Nemcansky J, Stepanov A, Kouber M, et al. Response to aflibercept therapy in three types of choroidal neovascular membrane in neovascular age-related macular degeneration: real-life evidence in the Czech Republic. J Ophthalmol. 2019;2:635-689.  https://doi.org/10.1155/2019/2635689
  32. Stepanov A, Nemcansky J, Veith M, et al. Two-year results of a combined regimen of aflibercept treatment in three types of choroidal neovascular membrane in the wet form of age-related macular degeneration: real-life evidence in the Czech Republic. Eur J Ophthalmol. 2020 Nov 16;1120672120971190. https://doi.org/10.1177/1120672120971190
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.